Company Of The Day: Pfizer
What?
Pfizer (NYSE:PFE) and its German partner BioNTech intend to begin clinical trials for an updated version of their Covid-19 vaccine that targets the Delta variant of the Coronavirus.
Why?
- What Factors Will Drive Pfizer’s Q1 Performance?
- After A 30% Fall In A Year Is Pfizer Stock A Better Pick Over Merck?
- Should You Pick Pfizer Stock At $30 After A 30% Fall In A Year?
- Should You Pick Pfizer Stock At $30?
- Down 25% In A Year Will Pfizer Stock Rebound To Its Pre-Inflation Shock Level?
- Will Pfizer Stock See Higher Levels Post Q1 Earnings?
The Delta variant apparently more transmissible compared to other strains of the virus. There are also concerns about the efficacy of the current generation of Covid-19 vaccines against the variant.
So What?
Pfizer and BioNtech are already generating windfall profits from their Covid-19 shot. Pfizer projects vaccine sales of $26 billion for this year – a conservative figure, in our view. With shots targeting new virus variants, the companies could keep their Covid vaccine sales going for a few more years.
See Our Complete Analysis For Pfizer
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market since 2016
See all Trefis Price Estimates and Download Trefis Data here
What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams